Enzon Pharma folds under pressure from shareholder activists

August 11th, 2008
| More
Today, Enzon Pharmaceuticals (ENZN) announced that it would give into shareholder activists' demands and try to sell all or parts of its commercial business, which include four marketed drugs, royalties and a manufacturing plant in Indiana. The company is also attempting to spin off its biotech research arm as its own company called Evivrus Inc, although the company will remain a wholly owned subsidiary of Enzon.

Enzon has been the target of shareholder activists Carl Icahn (7% stake in ENZN) and DellaCamera Capital Management (6.4% stake in ENZN), Both of these hedge fund firms have critical of ENZN's executive compensation and both have been pushing for a sale of its commercial businesses.
For Detailed Investor Profiles on these Investors, click below:
DellaCamera Capital Management
Icahn Associates (Carl Icahn)
Related People: Alexander J. Denner; Andrew J. Kurtz; Brett Icahn; Carl Icahn; Keith A. Meister*; Ralph DellaCamera; Richard Mansouri
Related Entities: DellaCamera Capital Advisors; DellaCamera Capital Partners LP; DellaCamera Options Inc; High River Limited Partnership; Icahn Partners; Icahn & Co Inc; Icahn Associates; Icahn Enterprises (formerly American Real Estate Partners); Icahn Fund Ltd; Icahn Partners LP
Related Article Tags: Shareholder Activists, Corporate Raiders and Proxy Battles; Hedge Fund Launches and Hedge Fund Closings


More Recent Headlines

James Pallotta to spins off Tudor funds into Raptor Global

Fortress gives $300 million share grant to Adam Levinson

Gabelli Wants Break Up of Cablevision

Steel Partners wants to put Point Blank in Range

Massachusetts State Pension Fund drops Bill Miller

Nationwide Mutual Insurance buys Nationwide Financial Services

Dow Kim cancels launch of Diamond Lake

Bristol-Myers Squibb Co. makes unsolicited bid for ImClone

Hedge funds adopting “operational activism” approach

T. Boone Pickens sells off his Yahoo shares at a loss